Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis

Exclusion Criteria

• •1. Guttate psoriasis, inverse psoriasis or exclusively involves the face;
• •2. Acute progression of psoriasis, and erythroderma tendency.Not blood stasis syndrome.Not stable psoriasis.
• •3. Pregnant, lactating, or which one plan to become pregnant in a year;
• •4. SAS（Self-rating Anxiety Scale）\> 50 or SDS（Self-rating Depression Scale）\> 53, or with other psychiatric disorders;
• •5. With history of cardiovascular, respiratory, digestive, urinary, and hematologic disease, which can't controlled through common treatment. Either with cancer, infection, electrolyte imbalance, acid-base disturbance and calcium metabolic disorder.
• •6. Allergic to any medicine or ingredients used in this study.
• •7. Participating other clinical trials or participated within 1 month.
• •8. Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks.
• •9. Patients need systemic treatment prescribed by doctors.